Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
148
-
Total 13F shares, excl. options
-
71.2M
-
Shares change
-
+37.5M
-
Total reported value, excl. options
-
$393M
-
Value change
-
+$199M
-
Put/Call ratio
-
0.29
-
Number of buys
-
111
-
Number of sells
-
-37
-
Price
-
$5.53
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q4 2018
176 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q4 2018.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 148 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 71.2M shares
of 236M outstanding shares and own 30.12% of the company stock.
Largest 10 shareholders include BAUPOST GROUP LLC/MA (24.5M shares), ABRAMS CAPITAL MANAGEMENT, L.P. (5.66M shares), Nantahala Capital Management, LLC (5.06M shares), Vanguard Group Inc (4.91M shares), Novo Holdings A/S (3.1M shares), STATE STREET CORP (2.64M shares), PERCEPTIVE ADVISORS LLC (1.7M shares), CITADEL ADVISORS LLC (1.44M shares), RICE HALL JAMES & ASSOCIATES, LLC (1.22M shares), and Clearbridge Investments, LLC (1.22M shares).
This table shows the top 148 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.